This site is intended for healthcare professionals registered in Ireland.
Menu
Safety DATA
TRIXEO: SAFETY AND TOLERABILITY PROFILE
The safety profile of Trixeo was consistent with the well-established profiles of its components1,2,6*
The most commonly reported adverse reactions in patients receiving this medicinal
product were pneumonia (4.6%), headache (2.7%) and urinary tract infection (2.7%)1
In trials of >10,000 patients, the most common adverse events (≥1%) included1,2,6.
*Budesonide (ICS), glycopyrronium (LAMA), and formoterol fumarate (LABA) †Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), and uncommon (≥1/1,000 to <1/100). Only the common and very common side effects are presented. Please refer to the Summary of Product Characteristics for the full list of adverse events.1
